Swiss Medica, Inc.

Swiss Medica, Inc.

January 06, 2005 08:01 ET

Swiss Medica Raises US$2.5 Million to Increase Size of the U.S. National Launch



OTC Bulletin Board SYMBOL: SWME

JANUARY 6, 2005 - 08:01 ET

Swiss Medica Raises US$2.5 Million to Increase Size of
the U.S. National Launch

TORONTO, ONTARIO--(CCNMatthews - Jan. 6, 2005) - Swiss Medica
(OTCBB:SWME)has significantly increased the size of its initial U.S.
national marketing budget for the O24™ Essential Oil Pain
Neutralizer, through the exercise of previously issued warrants, which
raised gross proceeds of US$2.5 million.

"We are pleased to have minimized shareholder dilution because these
warrants were issued in March 2004 and were already part of the
company's existing capital structure," said Chief Executive Officer
Raghu Kilambi. "These new funds substantially increase the breadth and
depth of the U.S. marketing campaign to launch the O24 pain relief
product in the highly competitive national pharmacy chain marketplace."

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve
chronic ailments. We increase our market share through focused
distribution strategies in multiple sales channels. Swiss Medica's
mission is to be a world leader in the commercialization of life
enhancing bioscience products that improve quality of lives. Please
visit our websites at and

Swiss Medica's flagship product, the O24™ Essential Oil Pain
Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief
solution has been used, recommended and praised for its fast-acting and
long-lasting benefits by healthcare professionals in the United States,
Canada and in Europe. O24 is widely available throughout Canada in
leading pharmacies and natural food stores. It is currently available in
Happy Harry's Discount Drugstores in the United States, or by visiting, for ordering details and store locators.

Forward-looking statements in this news release are made pursuant to the
"Safe Harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties, including,
without limitation, risks relating to the ability to close transactions
being contemplated, risks related to international sales and potential
foreign currency exchange fluctuations, continued acceptance of Swiss
Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks
detailed from time to time in Swiss Medica's periodic reports filed with
the United States Securities and Exchange Commission and other
regulatory authorities.


Contact Information

    Swiss Medica
    David Jones
    Investor Relations Contact
    1 (866) 485 4243
    Blue Skye PR, Inc.
    Sky Wallen
    Press Contact
    (813) 732-6869